Press Releases

The U.S. Women Health Laboratory Testing market is expected to grow at a CAGR of 4.5% during the forecast period. Women's health laboratory testing is a medical procedure involving diagnosing and treating female conditions and diseases. Sexually transmitted infections (STIs), gynecology disorders, breast cancer, ovarian cancer, and other diseases and disorders can develop in women, and this is where women's health laboratory testing plays a significant role. The primary drivers for the market growth of U.S. women health laboratory testing include the rising prevalence of infectious diseases like cancer, HIV, hepatitis, Urinary Tract Infections, etc., increased awareness about various health disorders among women, rising number of diagnostic and imaging centers, rising demand for fertility testing monitors, and surge in adoption of point-of-care diagnostic testing and PST practices, thereby propelling market development of U.S. Women Health Laboratory Testing Industry. Nevertheless, some of the key opportunities in the U.S. women's health laboratory testing market are breakthroughs in diagnostic technologies, including applications of genetic testing in women's health, and a surge in the number of mergers and acquisitions of companies to gain a larger market share.

In December 2022, Quest Diagnostics, the world's leading provider of diagnostic information services, and Northern Light Health, a large integrated healthcare system in Maine, announced a strategic laboratory collaboration to expand access to innovative, high-quality, and cost-effective laboratory services, enabling communities in Maine to receive affordable care.

Bowse 53 market data Tables and 35 Figures spread through 210 Pages and in-depth TOC on "U.S. Women Health Laboratory Testing Market by Cancer (Cervical Cancer, Breast Cancer, and Ovarian Cancer), by Prenatal Screening and Diagnostic Testing (Non-Invasive Prenatal Testing (NIPT), Maternal Serum Screening (MSS), Prenatal Diagnostic Testing), by Reproductive Health and Infectious Diseases (Pregnancy and Ovulation Testing, HPV Testing, PAP Smear Testing, HIV Testing, CT/NG Testing, Preimplantation Genetic Testing (PGT), Sexually Transmitted Infections, Herpes Simplex Virus (HSV), Hepatitis, and Vaginal Infections), and Region - U.S. Forecast to 2030

By cancer, breast cancer will witness significant market growth during the forecast period.

Based on Cancer, the U.S. Women Health Laboratory Testing Market is segmented into Cervical Cancer, Breast Cancer, and Ovarian Cancer. Breast Cancer is expected to have significant growth during the projected timeframe owing to the rising prevalence of breast cancer leading to increased breast cancer tests. Moreover, Breast cancer is the most common cancer in women and the second most common cancer in the world. A significant increase in the number of breast cancer patients is anticipated to boost the market demand for breast cancer diagnostics.

U.S. Women Health Laboratory Testing Market Segmentation and Key Players

Discover More About This Report, Download A Free Sample Copy of the U.S. Women Health Laboratory Testing Market

“South Region is expected to witness largest growth during the forecast period in the U.S. Women Health Laboratory Testing Market.”

South region is anticipated to grow at a higher pace during the forecast period. The increased emphasis on manufacturers to expand the presence of women’s health diagnostic products in the region, increased government and health organization initiatives, an upsurge in the rate of pregnancy, and increasing medical tourism will propel market development in the Health Laboratory Testing Market.

Some of the major players in the U.S. Women Health Laboratory Testing industry include F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., DiaSorin S.p.A, Natera, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics Incorporated, Abbott, Cardinal Health, and GE HealthCare.

U.S. Women Health Laboratory Testing Market Coverage

Cancer Insight and Forecast 2025-2030

• Cervical Cancer
• Breast Cancer
• Ovarian Cancer

Prenatal Screening and Diagnostic Testing Insight and Forecast 2025-2030

• Non-Invasive Prenatal Testing (NIPT)
• Maternal Serum Screening (MSS)
• Prenatal Diagnostic Testing

Reproductive Health and Infectious Diseases Insight and Forecast 2025-2030

• Pregnancy and Ovulation Testing
• HPV Testing
• PAP Smear Testing
• HIV Testing
• CT/NG Testing
• Preimplantation Genetic Testing (PGT)
• Sexually Transmitted Infections
• Herpes Simplex Virus (HSV)
• Hepatitis
• Vaginal Infections

Geographical Segmentation

U.S. Women Health Laboratory Testing Market by Region

Northeast Region

• By Cancer
• By Prenatal Screening and Diagnostic Testing
• By Reproductive Health and Infectious Diseases
• By Country – Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Puerto Rico, Rhode Island, Vermont, Virgin Islands, Virginia and West Virginia

Midwest Region

• By Cancer
• By Prenatal Screening and Diagnostic Testing
• By Reproductive Health and Infectious Diseases
• By Country – Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin

South Region

• By Cancer
• By Prenatal Screening and Diagnostic Testing
• By Reproductive Health and Infectious Diseases
• By Country – Alabama, Arkansas, Georgia, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, Tennessee

West Region

• By Cancer
• By Prenatal Screening and Diagnostic Testing
• By Reproductive Health and Infectious Diseases
• By Country – Alaska, Arizona, California, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming